Xtant Medical publishes 2025 annual report

Xtant Medical Holdings, Inc.

XTNT

0.00

Xtant Medical filed its 2025 annual report, highlighting a turnaround to profitability on improved operating execution.
Portfolio reshaped through the sale of non-core Coflex, CoFix, and international hardware assets to Companion Spine for USD 21.4 million.
Biologics strategy advanced through vertical integration, facility consolidation, and logistics changes aimed at tighter supply control and lower costs.
Commercial mix shifted toward private label growth; the independent agent channel lost share, prompting a 2026 rebuild plan.
2026 priorities include expanding the sales footprint, adding adjacent-market products such as HEMOBLAST Bellows, and accelerating new biologics launches.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.